scholarly journals Quantification of the effect of the upper-limb reflex-inhibition-posture on the upper-limb muscle tone and lower-limb spasticity in hemiplegic patients

2000 ◽  
Vol 24 (3) ◽  
pp. 174-182
Author(s):  
Shinji Miyazaki ◽  
Toshio Kubota
Keyword(s):  
Upper Limb ◽  
Lower Limb ◽  
Muscle Tone ◽  
Reflex Inhibition ◽  
Limb Muscle ◽  
Limb Spasticity ◽  
Lower Limb Spasticity

scholarly journals Efficacy and Safety of Botulinum Toxin Type A for Limb Spasticity after Stroke: A Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-17 ◽  
Author(s):  
Li-Chun Sun ◽  
Rong Chen ◽  
Chuan Fu ◽  
Ying Chen ◽  
Qianli Wu ◽  
...  
Keyword(s):  
Upper Limb ◽  
Lower Limb ◽  
Muscle Tone ◽  
Meta Analysis ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Physician Global Assessment ◽  
Randomized Controlled ◽  
Limb Spasticity ◽  
Lower Limb Spasticity

Background. Inconsistent data have been reported for the effectiveness of intramuscular botulinum toxin type A (BTXA) in patients with limb spasticity after stroke. This meta-analysis of available randomized controlled trials (RCTs) aimed to determine the efficacy and safety of BTXA in adult patients with upper and lower limb spasticity after stroke. Methods. An electronic search was performed to select eligible RCTs in PubMed, Embase, and the Cochrane library through December 2018. Summary standard mean differences (SMDs) and relative risk (RR) values with corresponding 95% confidence intervals (CIs) were employed to assess effectiveness and safety outcomes, respectively. Results. Twenty-seven RCTs involving a total of 2,793 patients met the inclusion criteria, including 16 and 9 trials assessing upper and lower limb spasticity cases, respectively. For upper limb spasticity, BTXA therapy significantly improved the levels of muscle tone (SMD=-0.76; 95% CI -0.97 to -0.55; P<0.001), physician global assessment (SMD=0.51; 95% CI 0.35-0.67; P<0.001), and disability assessment scale (SMD=-0.30; 95% CI -0.40 to -0.20; P<0.001), with no significant effects on active upper limb function (SMD=0.49; 95% CI -0.08 to 1.07; P=0.093) and adverse events (RR=1.18; 95% CI 0.72-1.93; P=0.509). For lower limb spasticity, BTXA therapy was associated with higher Fugl-Meyer score (SMD=5.09; 95%CI 2.16-8.01; P=0.001), but had no significant effects on muscle tone (SMD=-0.12; 95% CI -0.83 to 0.59; P=0.736), gait speed (SMD=0.06; 95% CI -0.02 to 0.15; P=0.116), and adverse events (RR=1.01; 95% CI 0.71-1.45; P=0.949). Conclusions. BTXA improves muscle tone, physician global assessment, and disability assessment scale in upper limb spasticity and increases the Fugl-Meyer score in lower limb spasticity.

OnabotulinumtoxinA Treatment in Patients with Upper Limb and Lower Limb Spasticity from the ASPIRE Study

2021 ◽  
Vol 102 (10) ◽  
pp. e21-e22
Author(s):  
Ganesh Bavikatte ◽  
Gerard Francisco ◽  
Alberto Esquenazi ◽  
Michael Dimyan ◽  
Kenneth Ngo ◽  
...  
Keyword(s):  
Upper Limb ◽  
Lower Limb ◽  
Limb Spasticity ◽  
Lower Limb Spasticity

scholarly journals HIV encephalopathy with bilateral lower limb spasticity: upper limb motor function and level of activity and participation

2016 ◽  
Vol 59 (4) ◽  
pp. 412-419 ◽  
Author(s):  
Theresa N Mann ◽  
Kirsten A Donald ◽  
Barbara Laughton ◽  
Robert P Lamberts ◽  
Nelleke G Langerak
Keyword(s):  
Motor Function ◽  
Upper Limb ◽  
Lower Limb ◽  
Hiv Encephalopathy ◽  
Level Of Activity ◽  
Bilateral Lower Limb ◽  
Limb Spasticity ◽  
Lower Limb Spasticity

Poster 75: Exploring Real-World OnabotulinumtoxinA Utilization Patterns for the Treatment of Lower Limb Spasticity: The Adult Spasticity International Registry (ASPIRE) Study

PM&R ◽  
2018 ◽  
Vol 10 ◽  
pp. S31-S31
Author(s):  
Alberto Esquenazi ◽  
Wolfgang H. Jost ◽  
Ganesh Bavikatte ◽  
Daniel S. Bandari ◽  
Michael C. Munin ◽  
...  
Keyword(s):  
Real World ◽  
Lower Limb ◽  
International Registry ◽  
Utilization Patterns ◽  
Limb Spasticity ◽  
Lower Limb Spasticity
Sign in / Sign up

Export Citation Format

Share Document